Robert W. Baird reaffirmed their buy rating on shares of Agilent Technologies (NYSE:A) in a research note issued to investors on Thursday morning. They currently have a $76.00 price target on the medical research company’s stock.

Several other research firms also recently issued reports on A. Zacks Investment Research raised Agilent Technologies from a hold rating to a buy rating and set a $76.00 price target for the company in a research note on Tuesday, October 31st. Barclays reaffirmed a buy rating and set a $74.00 price target on shares of Agilent Technologies in a research note on Monday, January 8th. Evercore ISI assumed coverage on Agilent Technologies in a research note on Wednesday, January 3rd. They set an outperform rating and a $75.00 price target for the company. Cowen reaffirmed a hold rating and set a $65.00 price target on shares of Agilent Technologies in a research note on Thursday, September 28th. Finally, ValuEngine downgraded Agilent Technologies from a buy rating to a hold rating in a research note on Friday, December 1st. Six equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $69.25.

Shares of Agilent Technologies (A) traded up $0.88 during midday trading on Thursday, hitting $73.07. 2,266,103 shares of the company’s stock traded hands, compared to its average volume of 1,760,000. The stock has a market cap of $23,520.00, a price-to-earnings ratio of 34.96, a P/E/G ratio of 2.18 and a beta of 1.28. Agilent Technologies has a 52 week low of $47.05 and a 52 week high of $73.21. The company has a quick ratio of 2.85, a current ratio of 3.30 and a debt-to-equity ratio of 0.37.

Agilent Technologies (NYSE:A) last issued its earnings results on Monday, November 20th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. Agilent Technologies had a net margin of 15.30% and a return on equity of 16.95%. The business’s revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.59 EPS. equities research analysts forecast that Agilent Technologies will post 2.58 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 2nd will be paid a $0.149 dividend. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.13. The ex-dividend date is Friday, December 29th. This represents a $0.60 annualized dividend and a yield of 0.82%. Agilent Technologies’s payout ratio is presently 28.71%.

In related news, VP Mark Doak sold 4,154 shares of the business’s stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $67.00, for a total value of $278,318.00. Following the completion of the transaction, the vice president now owns 68,270 shares of the company’s stock, valued at approximately $4,574,090. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael R. Mcmullen sold 22,481 shares of the business’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $70.00, for a total transaction of $1,573,670.00. Following the completion of the transaction, the chief executive officer now directly owns 327,882 shares of the company’s stock, valued at approximately $22,951,740. The disclosure for this sale can be found here. Insiders sold a total of 198,141 shares of company stock valued at $13,830,045 in the last three months.

Institutional investors and hedge funds have recently bought and sold shares of the business. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in Agilent Technologies by 9.9% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 998,225 shares of the medical research company’s stock valued at $64,086,000 after buying an additional 90,317 shares during the period. Timber Hill LLC purchased a new stake in Agilent Technologies in the 3rd quarter valued at about $1,672,000. Colony Group LLC purchased a new stake in Agilent Technologies in the 2nd quarter valued at about $260,000. Fisher Asset Management LLC purchased a new stake in Agilent Technologies in the 3rd quarter valued at about $609,000. Finally, Chevy Chase Trust Holdings Inc. grew its holdings in Agilent Technologies by 0.9% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 282,115 shares of the medical research company’s stock valued at $18,112,000 after buying an additional 2,599 shares during the period.

WARNING: This report was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2018/01/19/agilent-technologies-a-rating-reiterated-by-robert-w-baird.html.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.